Last reviewed · How we verify
KPS-0373, High dose
KPS-0373 is a selective TRPV1 antagonist that blocks pain signaling through the transient receptor potential vanilloid 1 channel.
KPS-0373 is a selective TRPV1 antagonist that blocks pain signaling through the transient receptor potential vanilloid 1 channel. Used for Chronic pain (Phase 3 development).
At a glance
| Generic name | KPS-0373, High dose |
|---|---|
| Sponsor | Kissei Pharmaceutical Co., Ltd. |
| Drug class | TRPV1 antagonist |
| Target | TRPV1 |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | Phase 3 |
Mechanism of action
TRPV1 is a key ion channel involved in nociception and pain transmission. By antagonizing TRPV1, KPS-0373 reduces the activation of pain-sensing neurons, thereby decreasing pain signal propagation to the central nervous system. This mechanism is being explored for chronic pain conditions where TRPV1 plays a significant role.
Approved indications
- Chronic pain (Phase 3 development)
Common side effects
- Hyperthermia or altered temperature sensation
- Gastrointestinal effects
Key clinical trials
- A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) (PHASE3)
- A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) (PHASE3)
- An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) (PHASE3)
- A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |